CA2480425A1 - Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation - Google Patents
Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation Download PDFInfo
- Publication number
- CA2480425A1 CA2480425A1 CA002480425A CA2480425A CA2480425A1 CA 2480425 A1 CA2480425 A1 CA 2480425A1 CA 002480425 A CA002480425 A CA 002480425A CA 2480425 A CA2480425 A CA 2480425A CA 2480425 A1 CA2480425 A1 CA 2480425A1
- Authority
- CA
- Canada
- Prior art keywords
- liquid preparation
- glycyl
- group
- preparation according
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002112864 | 2002-04-16 | ||
| JPNO.2002-112864 | 2002-04-16 | ||
| PCT/JP2003/004745 WO2003086471A2 (en) | 2002-04-16 | 2003-04-15 | Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2480425A1 true CA2480425A1 (en) | 2003-10-23 |
Family
ID=29243336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002480425A Abandoned CA2480425A1 (en) | 2002-04-16 | 2003-04-15 | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20050215485A1 (https=) |
| EP (1) | EP1501549A2 (https=) |
| JP (1) | JP3927954B2 (https=) |
| KR (1) | KR100700963B1 (https=) |
| CN (1) | CN100544769C (https=) |
| AR (1) | AR039272A1 (https=) |
| AU (1) | AU2003223120B2 (https=) |
| BR (1) | BR0309283A (https=) |
| CA (1) | CA2480425A1 (https=) |
| HR (1) | HRP20040894A2 (https=) |
| ME (1) | MEP31308A (https=) |
| MX (1) | MXPA04010178A (https=) |
| MY (1) | MY136696A (https=) |
| NO (1) | NO20044964L (https=) |
| PL (1) | PL371677A1 (https=) |
| RS (1) | RS91204A (https=) |
| RU (1) | RU2315623C2 (https=) |
| TW (1) | TW200306314A (https=) |
| UA (1) | UA77295C2 (https=) |
| WO (1) | WO2003086471A2 (https=) |
| ZA (1) | ZA200408008B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005024923D1 (de) * | 2004-02-13 | 2011-01-05 | Yakult Honsha Kk | Wässrige lösung mit einem camptothecin |
| US20070207149A1 (en) | 2004-04-27 | 2007-09-06 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
| US7767200B2 (en) | 2005-07-14 | 2010-08-03 | Wellstat Biologics Corporation | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
| JP2007260275A (ja) * | 2006-03-29 | 2007-10-11 | Transcutaneous Technologies Inc | イオントフォレーシス装置及びイオントフォレーシス投与用組成物 |
| SA110310528B1 (ar) | 2009-06-22 | 2014-07-02 | Wyeth Llc | التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس |
| SG10201406432RA (en) | 2009-06-22 | 2014-11-27 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| CN102764260B (zh) * | 2011-04-30 | 2014-07-30 | 正大天晴药业集团股份有限公司 | 一种喜树碱衍生物的药物组合物及其制备方法 |
| JP5983608B2 (ja) * | 2011-07-15 | 2016-09-06 | コニカミノルタ株式会社 | 溶解助剤を利用したリポソーム含有製剤およびその製造方法 |
| RU2717690C2 (ru) | 2014-12-26 | 2020-03-25 | Ниппон Каяку Кабусики Каися | Фармацевтический состав полимерного производного, содержащего камптотецин |
| KR20180039628A (ko) | 2015-09-03 | 2018-04-18 | 니폰 가야꾸 가부시끼가이샤 | 캄프토테신류 고분자 유도체를 함유하는 의약 조성물 |
| AU2016326747A1 (en) | 2015-09-25 | 2018-03-01 | Zy Therapeutics Inc. | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate |
| RU2018129760A (ru) | 2016-03-01 | 2020-04-01 | Ниппон Каяку Кабусики Кайся | Фармацевтический препарат, содержащий полимерное производное на основе камптотецина |
| CN109481691A (zh) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | 吉西他滨-羧甲基多糖共轭物、制备方法及其用途 |
| KR20240105503A (ko) * | 2021-11-26 | 2024-07-05 | 아스테라스 세이야쿠 가부시키가이샤 | 인도시아닌 화합물 함유 고형 의약 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340817A (en) * | 1987-04-14 | 1994-08-23 | Research Triangle Institute | Method of treating tumors with anti-tumor effective camptothecin compounds |
| EP0540099B1 (en) * | 1991-10-29 | 1996-04-17 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| IT1282673B1 (it) * | 1996-02-23 | 1998-03-31 | Ist Naz Stud Cura Dei Tumori | Derivati della camptotecina e loro uso come agenti antitumorali |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| US6288072B1 (en) * | 1999-12-29 | 2001-09-11 | Monroe E. Wall | Camptothecin β-alanine esters with topoisomerase I inhibition |
| AR030207A1 (es) * | 2000-04-07 | 2003-08-13 | Daiichi Seiyaku Co | Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma |
| AU2001271037A1 (en) * | 2000-07-13 | 2002-01-30 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing dds compounds |
| TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
-
2003
- 2003-04-01 TW TW092107354A patent/TW200306314A/zh unknown
- 2003-04-09 AR ARP030101238A patent/AR039272A1/es unknown
- 2003-04-11 MY MYPI20031367A patent/MY136696A/en unknown
- 2003-04-15 PL PL03371677A patent/PL371677A1/xx not_active Application Discontinuation
- 2003-04-15 UA UA20041109367A patent/UA77295C2/uk unknown
- 2003-04-15 RS YU91204A patent/RS91204A/sr unknown
- 2003-04-15 RU RU2004133349/15A patent/RU2315623C2/ru not_active IP Right Cessation
- 2003-04-15 JP JP2003587152A patent/JP3927954B2/ja not_active Expired - Fee Related
- 2003-04-15 BR BR0309283-6A patent/BR0309283A/pt not_active IP Right Cessation
- 2003-04-15 AU AU2003223120A patent/AU2003223120B2/en not_active Ceased
- 2003-04-15 CA CA002480425A patent/CA2480425A1/en not_active Abandoned
- 2003-04-15 MX MXPA04010178A patent/MXPA04010178A/es active IP Right Grant
- 2003-04-15 ME MEP-313/08A patent/MEP31308A/xx unknown
- 2003-04-15 HR HR20040894A patent/HRP20040894A2/xx not_active Application Discontinuation
- 2003-04-15 EP EP03719110A patent/EP1501549A2/en not_active Withdrawn
- 2003-04-15 WO PCT/JP2003/004745 patent/WO2003086471A2/en not_active Ceased
- 2003-04-15 CN CNB038082292A patent/CN100544769C/zh not_active Expired - Fee Related
- 2003-04-15 US US10/509,912 patent/US20050215485A1/en not_active Abandoned
- 2003-04-15 KR KR1020047016514A patent/KR100700963B1/ko not_active Expired - Fee Related
-
2004
- 2004-10-05 ZA ZA200408008A patent/ZA200408008B/en unknown
- 2004-11-15 NO NO20044964A patent/NO20044964L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003223120A2 (en) | 2003-10-27 |
| RU2315623C2 (ru) | 2008-01-27 |
| RU2004133349A (ru) | 2005-05-27 |
| WO2003086471A3 (en) | 2004-04-15 |
| TW200306314A (en) | 2003-11-16 |
| AR039272A1 (es) | 2005-02-16 |
| JP2005523329A (ja) | 2005-08-04 |
| JP3927954B2 (ja) | 2007-06-13 |
| MEP31308A (en) | 2010-10-10 |
| UA77295C2 (en) | 2006-11-15 |
| AU2003223120A1 (en) | 2003-10-27 |
| MY136696A (en) | 2008-11-28 |
| NO20044964L (no) | 2004-11-15 |
| RS91204A (sr) | 2006-12-15 |
| CN100544769C (zh) | 2009-09-30 |
| US20050215485A1 (en) | 2005-09-29 |
| KR100700963B1 (ko) | 2007-03-28 |
| KR20050000516A (ko) | 2005-01-05 |
| MXPA04010178A (es) | 2005-06-08 |
| PL371677A1 (en) | 2005-06-27 |
| BR0309283A (pt) | 2005-02-15 |
| EP1501549A2 (en) | 2005-02-02 |
| CN1646172A (zh) | 2005-07-27 |
| ZA200408008B (en) | 2005-06-13 |
| HRP20040894A2 (en) | 2005-10-31 |
| AU2003223120B2 (en) | 2006-10-05 |
| WO2003086471A2 (en) | 2003-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101502533B1 (ko) | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 | |
| CA2480425A1 (en) | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation | |
| WO2007095850A1 (en) | A pharmaceutical composition of docetaxel, preparation and use | |
| AU2003235401A1 (en) | Medicinal compositions containing ghrelin | |
| JP2002363097A (ja) | 安定化された凍結乾燥型医薬組成物 | |
| JP2006137678A (ja) | インターロイキン−２組成物 | |
| EA036982B1 (ru) | Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин с | |
| WO2015038431A1 (en) | Stable compositions of peptide epoxy ketones | |
| JP4142149B2 (ja) | バンコマイシンの凍結乾燥製剤 | |
| JP2007500191A (ja) | Ｃｃｉ−７７９の凍結乾燥処方 | |
| JPH05331071A (ja) | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 | |
| US20220000792A1 (en) | Albumin pharmaceutical composition and preparation method therefor | |
| US12564619B2 (en) | Stable formulations of recombinant proteins | |
| CA2809646C (en) | 5.alpha.-androstane-3.beta.,5,6.beta.-triol injection and preparation method therefor | |
| US12491229B2 (en) | Stabilized peptide composition | |
| US11957758B2 (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
| WO2022265591A1 (en) | Pharmaceutical compositions of bevacizumab | |
| JPH08231398A (ja) | 凍結乾燥製剤 | |
| US20030139468A1 (en) | Amiodarone solutions suitable for intravenous administration | |
| JPH05967A (ja) | 組織プラスミノーゲンアクチベーター含有製剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |